Johnson & Johnson’s $6.5 Billion Acquisition of Momenta Pharmaceuticals, Inc.

On August 19, 2020, Johnson & Johnson announced that it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. The acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. Cravath is representing Johnson & Johnson in connection with the transaction.

The Cravath team is led by partner Robert I. Townsend III and includes associates Jin-Kyu Baek, James Ding, Ty A. Carleton and Jerome C. Newton on M&A matters; partner J. Leonard Teti II and associate Andrew T. Davis on tax matters; partner David J. Kappos, practice area attorney Anthony N. Magistrale and associate Ryan J. Wichtowski on intellectual property matters, partner Jonathan J. Katz and associates Matthew J. Bobby and Dixing Tang on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; and practice area attorney Brian M. Budnick on real estate matters.